Founded Year



Unattributed VC | Alive

Total Raised


Last Raised

$15M | 3 yrs ago

About Qlarity Imaging

Qlarity Imaging improves patient care by extracting clinical insights from existing medical images. It builds products that give radiologists information they do not have access to today.

Qlarity Imaging Headquarter Location

330 N Wabash Suite 3500

Chicago, Illinois, 60611,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Qlarity Imaging's Products & Differentiation

See Qlarity Imaging's products and how their products differentiate from alternatives and competitors

  • QuantX™

    1. At the core of QuantX™ is a proprietary AI algorithm that synthesizes 34 radiomic and morphological features into the QuantX Score™—a single value related to the likelihood of malignancy based on comparative analysis to lesions with known outcomes. 2. QuantX™ is transitioning to be a vendor-neutral solution that leverages the current PACS environment and automatically exports findings to the reporting application. This new format is currently in development. 3. QuantX™ will be deployed as a SaaS application to encourage 24/7 accessibility and increased distribution options with partners, providing more value to customers. This new format is currently in development.

Expert Collections containing Qlarity Imaging

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Qlarity Imaging is included in 5 Expert Collections, including Medical Devices.


Medical Devices

11,392 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health Monitoring & Diagnostics

2,707 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance


Digital Hospital

98 items

Startups recreating how healthcare is delivered


Digital Health

13,070 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

10,540 items

This collection includes public and private companies, as well as startups, that market software solutions to healthcare provider organizations.

Latest Qlarity Imaging News

05:30 ET Breast Cancer Screening Market Size Worth $6,209.25 Mn, Globally, by 2027 at 4.8% CAGR - Exclusive Report by The Insigh...

Dec 15, 2021

Share this article Share this article NEW YORK, Dec. 15, 2021 /PRNewswire/ -- According to the new market research report " Breast Cancer Screening Market  Forecast to 2027 - COVID-19 Impact and Global Analysis by Test Type (Blood Marker tests, Imaging Test, Genetic Test, Immunohistochemistry Test); End User (Hospitals, Diagnostic Centers, Cancer Institutes, Research Laboratories), and Geography", published by The Insight Partners, the global breast cancer screening market is expected to reach US$ 6,209.25 Mn by 2027 from US$ 4,638.63 Mn in 2019; it is estimated to grow at a CAGR of 4.8% from 2020 to 2027. Get the Latest COVID-19 Analysis on breast cancer screening market at Breast Cancer Screening Market: Competition Landscape and Key Developments Koninklijke Philips N.V., Hologic, Inc., BD, Myriad Genetics, Inc., Siemens Healthcare Gmbh, Exact Sciences Corporation, Oncocyte Corporation, POC Medical Systems, Danaher, and General Electric Company are among the key companies operating in the breast cancer screening market. These players are focusing on the expansion and diversification of their market presence and the acquisition of a new customer base, thereby tapping prevailing business opportunities. In March 2018, Philips and Hologic performed global partnership agreement to provide integrated imaging solutions for women's health. This partnership is likely to make it possible for clinics to obtain interconnected suites of medical imaging modalities, sophisticated engineering and extensive breast screening and testing facilities. In May 2018, Siemens Healthineers and ScreenPoint Medical has performed collaboration in designing breast imaging software focused on artificial intelligence. This joint partnership also includes Siemens Healthineers owning a strategic minority interest in ScreenPoint Medical. In August 2018, OncoCyte Corporation performed a partnership/collaboration process with Insight Genetics. This Partnership will increase the product portfolio in breast cancer imaging area. North America held the largest share of the breast cancer screening market in 2019, and it is likely to continue its dominance in terms of market share during the forecast period. The US held the largest share of the breast cancer screening market in North America, and the growth of this market is ascribed to significant research and development spending for breast cancer, availability of advanced technologies, and greater emphasis on early breast cancer screening in the country. Further, the market in Canada and Mexico is expected to grow with increasing investments for early breast cancer diagnostics and rising government initiatives for its prevention and control. Get Exclusive Sample Pages of Breast Cancer Screening Market Size - COVID-19 Impact and Global Analysis with Strategic Insights at According to the WHO, the most common type of cancer incident in the US is breast cancer, and there were around 234,087 breast cancer cases and 41,904 deaths due to breast cancer in 2018. Furthermore, the American Cancer Society has estimated that there will be around 276,480 new cases expected in the United States in 2020. Furthermore, many market players are conducting research and developing new products for breast cancer screening. For instance, in December 2019, Paragon Biosciences LLC, located in Chicago, US, established Qlarity Imaging LLC, US, which will develop QuantX, the innovative U.S. Food and Drug Administration (FDA)-cleared computer-aided breast cancer diagnosis system in radiology. Thus, the development of such technologies will advance the diagnostic techniques for breast cancer. Moreover, the national breast and cervical cancer early detection program by the CDC offers early breast and cervical cancer screening and diagnostic services to low-income, uninsured, and underserved women and also supports strategies to increase screening rates. Thus, such programs can help diagnose breast and cervical cancer at the earliest stages. Asia Pacific is expected to register the highest CAGR in the global breast cancer screening market during the forecast period. Countries such as China, Japan, and India are expected to be the major contributors to the market in this region during 2020–2027. The growth of the market in Asia Pacific is attributed to rising support from the government, increasing prevalence of breast cancer, escalating number of start-ups operating in the market, and widening reach of international players in the region. Growing Breast Cancer Prevalence in Breast Cancer Screening Market: Breast cancer is among the prime causes of deaths in the world, and it is profoundly affecting the quality of life. Thus, it acts as a burden on society if not diagnosed and treated on time. As per the estimations by the American Cancer Society, breast cancer is the most common type of cancer in the US as it caused morbidity in ~234,087 people and lead to 41,904 deaths in 2018. Further, ~276,480 new cases are expected in the country in 2020. As per the Globocan 2019 report, in Germany, the total number of breast cancer cases in 2018 was 71,888, and around the disease lead to ~19,376 deaths in that year. Download Sample PDF Brochure of Breast Cancer Screening Market Size and Growth Research Report at Further, as per the Globocan report, in 2018, there were ~367,900 new cases of breast cancer and 97,972 deaths due to the same in China. In India, NGOs, government agencies, and charity organizations are emphasizing on breast cancer awareness among population to promote early detection, provide comprehensive treatment module, and extend support for breast cancer management. Such initiatives are a result of the increasing prevalence of this type of cancer in the country. As per the Globocan report estimation, in 2018, India reported ~162,468 new breast cancer cases and 87,090 deaths due to the same. Such growing prevalence of breast cancer in different regions around the world is raising the global demand for the screening devices for the same. Breast Cancer Screening Market: Segmental Overview Based on mobility, the breast cancer screening market is segmented into is segmented into blood marker test, imaging test, genetic test, andimmunohistochemistry test. The imaging test segment accounted for more than 46.96% of the market share in 2019. In terms of end user, the breast cancer screening market is segmented into hospitals, diagnostic centers, cancer institutes, and research laboratories. The hospitals segment held the largest share of the market in 2019. The COVID-19 outbreak has disturbed various trades and businesses across the world. Due to coronavirus spreading, many cities are shutting down causing treatments and doctors appointment cancellation. Patients with serious health conditions, such as breast cancer needs physical distancing with others, however, delays in cancer treatments is distressing. According to the, In the United States, many doctors, hospitals and other healthcare facilities are delaying or canceling the breast cancer procedures, surgeries and sometimes screenings or other treatments, if it is not considered urgent, emergencies, or otherwise indicated for life-threatening conditions. Breast cancer patients are requested to social distancing as they are more prone to get infected with coronavirus due to weak immune system. Therefore, it is likely to affect breast cancer screening market owing to above mention points. Buy Premium Copy of Breast Cancer Screening Market Size, Share, Revenue, Strategic Insights and Forecasts 2020-2027 Research Report at About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Sameer Joshi

Qlarity Imaging Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Qlarity Imaging Rank

  • When was Qlarity Imaging founded?

    Qlarity Imaging was founded in 2018.

  • Where is Qlarity Imaging's headquarters?

    Qlarity Imaging's headquarters is located at 330 N Wabash, Chicago.

  • What is Qlarity Imaging's latest funding round?

    Qlarity Imaging's latest funding round is Unattributed VC.

  • How much did Qlarity Imaging raise?

    Qlarity Imaging raised a total of $15M.

  • Who are the investors of Qlarity Imaging?

    Investors of Qlarity Imaging include Valor Equity Partners.

  • Who are Qlarity Imaging's competitors?

    Competitors of Qlarity Imaging include Philips Lifeline and 3 more.

  • What products does Qlarity Imaging offer?

    Qlarity Imaging's products include QuantX™.

You May Also Like

Sensome Logo

Sensome develops micro-sensor technology for smart medical devices. Sensome's sensing technology can be integrated with any medical device to reliably identify biological tissues in contact with the device. The technology combines micrometric impedance sensors that communicate wirelessly outside the body and machine learning algorithms for accurate and predictive real-time analysis.

BrightInsight Logo

BrightInsight provides a global platform for biopharma and MedTech regulated digital health solutions. The company helps accelerate time to market for apps, algorithms, medical devices, connected combination products, diagnostics, and Software as a Medical Device (SaMD). BrightInsight offers configurable software modules and a proven platform built under a Quality Management System to support global security, privacy, and regulatory requirements. When building digital health products on the BrightInsight Platform, compliance is future-proofed as intended use changes scale across geographies. Logo offers a cloud-based service that enables companies to process the diagnostics data they collect about their applications.

Smabbler Logo

Smabbler is a unified artificial general intelligence system with language cognitive capabilities enabling machine reasoning from human language and automated handling of big unstructured text data.


CapeRay develops the PantoScanner platform, breast imaging technology to detect malignant cancer in dense breast tissue.

Biotwin Logo

Biotwin empowers health professionals with data-driven and technological solutions to help them make better decisions and recommendations

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.